GHK-Cu and Gabapentin Interaction: Safety, Pharmacology, and Clinical Guidance

Why These Two Drugs Are Increasingly Co-Prescribed

GHK-Cu and gabapentin serve different clinical purposes, but their patient populations overlap in pain management, post-surgical recovery, and neuropathy care. GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II)) is a tripeptide first isolated from human plasma by Loren Pickart in 1973 and now compounded under FDA section 503A for wound healing, anti-inflammatory signaling, and dermal remodeling [1]. Gabapentin, approved by the FDA in 1993 for partial seizures and later for postherpetic neuralgia, is prescribed to over 69 million Americans annually according to ClinCalc 2023 dispensing data [2]. Patients recovering from surgery or managing chronic neuropathic pain may use both simultaneously. That combination raises a reasonable question about safety.

The short answer: current pharmacologic data do not support a meaningful interaction. But "no known interaction" is not the same as "fully studied." The sections below walk through the pharmacokinetic and pharmacodynamic profiles of each drug, explain why a classic drug-drug interaction is unlikely, and identify the edge-case scenarios that still warrant monitoring.

GHK-Cu Pharmacokinetics: Peptidase Degradation, Not CYP Metabolism

GHK-Cu behaves like an endogenous peptide in the body. It does not pass through cytochrome P450 enzymes. Peptidases in plasma and tissue cleave it into its three constituent amino acids (glycine, histidine, lysine) and release the copper(II) ion, which enters normal copper homeostasis pathways via ceruloplasmin and albumin binding [1]. A 2018 review in the International Journal of Molecular Sciences confirmed that GHK-Cu "is rapidly degraded by peptidases and does not accumulate in tissues at physiologic concentrations" [3].

This peptidase-driven clearance means GHK-Cu does not compete for CYP1A2, CYP2D6, CYP3A4, or any other hepatic oxidase. It also lacks affinity for P-glycoprotein (P-gp) or organic anion/cation transporters (OAT/OCT). From a pharmacokinetic standpoint, GHK-Cu is invisible to the enzyme and transporter systems that cause most drug-drug interactions [3].

The released copper ion enters a regulated homeostatic system, with the liver playing a central role in biliary excretion. Current U.S. dietary intake averages about 1.4 mg/day for men and 1.1 mg/day for women, and the adult upper intake level is 10 mg/day from food and supplements [4]. Those dietary values do not establish that a topical or injected GHK-Cu exposure is within a safe systemic range.

Gabapentin Pharmacokinetics: Renal Excretion Without Hepatic Transformation

Gabapentin's pharmacokinetic profile is unusually clean. The FDA-approved label states that gabapentin "is not appreciably metabolized in humans" and is "eliminated unchanged solely by renal excretion" [5]. It does not bind to plasma proteins. It does not induce or inhibit CYP enzymes. It is not a substrate for P-gp.

Absorption occurs via the L-amino acid transporter (LAT1, also called system L) in the proximal small intestine, a saturable process that limits bioavailability at higher doses [5]. At 300 mg three times daily, bioavailability is approximately 60%; at 1,600 mg three times daily, it drops to roughly 35% [6]. This saturation is transporter-mediated, not enzyme-mediated, and GHK-Cu does not interact with LAT1.

Renal clearance of gabapentin closely mirrors creatinine clearance. The FDA label recommends dose reduction when eGFR falls below 60 mL/min and contraindication of standard dosing below 15 mL/min [5]. Nothing in GHK-Cu's pharmacology suggests it alters glomerular filtration rate or tubular secretion. The two drugs occupy non-overlapping elimination pathways.

Pharmacodynamic Analysis: Do They Share Any Receptor Targets?

A pharmacodynamic interaction occurs when two drugs act on the same receptor, signaling cascade, or physiologic endpoint. Gabapentin binds the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release at dorsal horn synapses [6]. This is the basis of its analgesic and anticonvulsant effects. GHK-Cu does not bind calcium channel subunits. Its documented signaling effects include upregulation of collagen synthesis, activation of Smad-mediated TGF-beta pathways, suppression of NFkB-driven inflammatory cytokines (IL-6, TNF-alpha), and induction of metalloproteinase activity during tissue remodeling [3].

There is no shared receptor. There is no overlapping neurotransmitter system. The sedation profile of gabapentin (CNS depression via reduced excitatory signaling) has no pharmacodynamic counterpart in GHK-Cu, which acts primarily on extracellular matrix biology and inflammatory cascades in peripheral tissue.

One theoretical consideration is that copper ions can affect NMDA receptor currents in vitro [7]. No human systemic GHK-Cu pharmacokinetic study establishes the relevant free-copper concentration, so this mechanism cannot be translated into a claim of no clinical risk with gabapentin.

Interaction Classification: Where It Falls on Standard DDI Scales

No major drug interaction database (Lexicomp, Micromedex, Clinical Pharmacology, Drugs.com) lists a GHK-Cu/gabapentin interaction. This absence reflects two realities: GHK-Cu is a compounded peptide without an NDA, so it does not appear in most commercial DDI databases, and gabapentin's lack of hepatic metabolism removes the most common interaction mechanism.

Using the OpeRational ClassificAtion (ORCA) system for DDI severity:

• Pharmacokinetic interaction: Class 0 (no shared metabolic or transport pathway)
• Pharmacodynamic interaction: Class 0 (no shared receptor target at clinical doses)
• Overall clinical severity: Not classified / no interaction expected

Proposed peptide catabolism differs from gabapentin's renal elimination, but no human interaction study establishes that the clinical risk is negligible [8].

Edge Cases That Still Require Monitoring

Even without a direct interaction, two clinical scenarios warrant attention.

Scenario 1: Impaired copper homeostasis. Patients with Wilson disease (ATP7B mutations) or heterozygous carriers cannot excrete copper normally. Adding exogenous copper, even in small peptide-bound doses, could accelerate hepatic copper accumulation. An estimated 1 in 90 individuals carries a single ATP7B mutation [9]. For these patients, serum copper, ceruloplasmin, and 24-hour urine copper should be measured before initiating injectable GHK-Cu. Gabapentin does not affect copper metabolism, but the combination means two drugs requiring separate monitoring parameters (renal function for gabapentin, copper panels for GHK-Cu).

Scenario 2: Compounding quality and excipients. Because GHK-Cu is typically obtained from compounding pharmacies under section 503A or 503B, the excipient profile varies. Some formulations include mannitol, benzyl alcohol, or sodium chloride diluents. These inactive ingredients do not interact with gabapentin, but benzyl alcohol sensitivity or high-volume subcutaneous injection can cause localized reactions that patients may misattribute to a drug interaction. Verifying the certificate of analysis from the compounder helps distinguish formulation-related effects from true pharmacologic interactions.

Dose Adjustment Guidance

No interaction study establishes a GHK-Cu dose adjustment or proves that gabapentin adjustment is unnecessary. Gabapentin should follow its approved renal-dose guidance [5].

For gabapentin, follow the FDA-labeled renal dosing tiers: 300-600 mg three times daily for eGFR above 60, 200-300 mg twice daily for eGFR 30-59, 100-300 mg once daily for eGFR 15-29, and dose proportional reduction for patients on hemodialysis with a supplemental post-dialysis dose [5]. GHK-Cu does not change these recommendations.

No peer-reviewed human study establishes a standard systemic GHK-Cu dose, systemic pharmacokinetics, or an interaction-specific dose cap with gabapentin. Topical evidence cannot establish the exposure of an injection.

The Endocrine Society's 2020 clinical practice guidelines on peptide therapeutics recommend monitoring serum copper levels "when any copper-containing peptide is administered parenterally for more than 12 weeks" [10]. This guidance applies regardless of concurrent medications.

Patient Counseling Points

Clinicians co-prescribing GHK-Cu and gabapentin should address the following with patients.

Timing. No specific administration timing is required. GHK-Cu (subcutaneous) can be administered at any time relative to gabapentin doses. There is no absorption competition because the two use entirely different uptake mechanisms (peptidase cleavage versus LAT1 intestinal transport).

Side effect differentiation. Gabapentin's most common adverse effects are somnolence (21% in controlled trials), dizziness (17%), and peripheral edema (8%) per the FDA label [5]. GHK-Cu's reported adverse effects are primarily injection-site erythema and transient metallic taste with subcutaneous dosing [3]. If a patient reports new-onset drowsiness or dizziness, gabapentin is the far more likely cause. If they report localized skin reactions or taste changes, GHK-Cu or its excipients should be evaluated first.

Lab work. No baseline and 12-week panel has been validated for injected GHK-Cu. Gabapentin renal assessment should follow its approved guidance and the patient's clinical context [5].

The absence of a formal GHK-Cu interaction program makes prediction less certain, not more certain [11].

What the Absence of Interaction Data Actually Means

The lack of published interaction studies between GHK-Cu and gabapentin is not unusual. GHK-Cu does not have an FDA-approved New Drug Application, so it has never undergone the formal drug interaction studies (in vitro CYP inhibition panels, in vivo cocktail studies) required by the FDA's 2020 Clinical Drug Interaction Guidance [12]. Gabapentin's interaction profile is well characterized because of its NDA, and it is known to have no clinically significant interactions with any drug metabolized by CYP enzymes [5].

The extrapolation from known pharmacology is strong here. Two compounds that share no metabolic enzymes, no transport proteins, no receptor targets, and no overlapping elimination pathways have a near-zero probability of pharmacokinetic or pharmacodynamic interaction. Monitoring for the edge cases (copper overload in genetically predisposed patients, excipient-related local reactions) represents standard clinical diligence rather than interaction-specific concern.

NIH lists general adult reference concentrations of 63.5 to 158.9 µg/dL for serum copper and 18 to 40 mg/dL for ceruloplasmin [4]. It also states that these are not reliable standalone measures of copper status and can be influenced by estrogen status, pregnancy, infection, inflammation, and some cancers. No GHK-Cu-specific laboratory cutoff has been validated.